FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105588894> ?p ?o ?g. }

• W2105588894 endingPage "2264" @default.
• W2105588894 startingPage "2257" @default.
• W2105588894 abstract "Purpose Specific adverse events (AEs) associated with endocrine therapy and related to depletion or blocking of circulating estrogens may be related to treatment efficacy. We investigated the relationship between survival outcomes and specific AEs including vasomotor symptoms (VMSs), musculoskeletal adverse events (MSAEs), and vulvovaginal symptoms (VVSs) in postmenopausal patients with breast cancer participating in the international Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. Patients and Methods Primary efficacy end points were disease-free survival (DFS), overall survival (OS), and distant metastases (DM). VMSs, MSAEs, and VVSs arising in the first year of endocrine treatment were considered. Patients who did not start or who discontinued their allocated therapy and/or had an event (recurrence/death) within 1 year after randomization were excluded. Landmark analyses and time-dependent multivariate Cox proportional hazards models assessed survival differences up to 5 years from the start of treatment. Results A total of 9,325 patients were included. Patients with specific AEs (v nonspecific or no AEs) had better DFS and OS (multivariate hazard ratio [HR] for DFS: VMSs, 0.731 [95% CI, 0.618 to 0.866]; MSAEs, 0.826 [95% CI, 0.694 to 0.982]; VVSs, 0.769 [95% CI, 0.585 to 1.01]; multivariate HR for OS: VMSs, 0.583 [95% CI, 0.424 to 0.803]; MSAEs, 0.811 [95% CI, 0.654 to 1.005]; VVSs, 0.570 [95% CI, 0.391 to 0.831]) and fewer DM (VMSs, 0.813 [95% CI, 0.664 to 0.996]; MSAEs, 0.749 [95% CI, 0.601 to 0.934]; VVSs, 0.687 [95% CI, 0.436 to 1.085]) than patients not reporting these symptoms. Increasing numbers of specific AEs were also associated with better survival outcomes. Outcomes were unrelated to treatment allocation. Conclusion Certain specific AEs are associated with superior survival outcomes and may therefore be useful in predicting treatment responses in patients with breast cancer treated with endocrine therapy." @default.
• W2105588894 created "2016-06-24" @default.
• W2105588894 creator A5001188276 @default.
• W2105588894 creator A5004831613 @default.
• W2105588894 creator A5008883508 @default.
• W2105588894 creator A5012337396 @default.
• W2105588894 creator A5017871390 @default.
• W2105588894 creator A5025411863 @default.
• W2105588894 creator A5026031837 @default.
• W2105588894 creator A5031668702 @default.
• W2105588894 creator A5038448622 @default.
• W2105588894 creator A5051306896 @default.
• W2105588894 creator A5052920067 @default.
• W2105588894 creator A5061318948 @default.
• W2105588894 creator A5068970824 @default.
• W2105588894 creator A5070338465 @default.
• W2105588894 creator A5073613763 @default.
• W2105588894 creator A5082393642 @default.
• W2105588894 creator A5091359426 @default.
• W2105588894 date "2013-06-20" @default.
• W2105588894 modified "2023-10-12" @default.
• W2105588894 title "Specific Adverse Events Predict Survival Benefit in Patients Treated With Tamoxifen or Aromatase Inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial Analysis" @default.
• W2105588894 cites W1519097020 @default.
• W2105588894 cites W1531964529 @default.
• W2105588894 cites W1540562253 @default.
• W2105588894 cites W1915891270 @default.
• W2105588894 cites W1966623655 @default.
• W2105588894 cites W1975236199 @default.
• W2105588894 cites W1983438740 @default.
• W2105588894 cites W1999460674 @default.
• W2105588894 cites W1999618586 @default.
• W2105588894 cites W2010162207 @default.
• W2105588894 cites W2021390995 @default.
• W2105588894 cites W2032449691 @default.
• W2105588894 cites W2041421713 @default.
• W2105588894 cites W2068069047 @default.
• W2105588894 cites W2071003201 @default.
• W2105588894 cites W2083095534 @default.
• W2105588894 cites W2114999889 @default.
• W2105588894 cites W2117572744 @default.
• W2105588894 cites W2121656289 @default.
• W2105588894 cites W2130160257 @default.
• W2105588894 cites W2135292833 @default.
• W2105588894 cites W2139023087 @default.
• W2105588894 cites W2148003100 @default.
• W2105588894 cites W2149589068 @default.
• W2105588894 cites W2149615486 @default.
• W2105588894 cites W2154734961 @default.
• W2105588894 cites W2166143114 @default.
• W2105588894 cites W2167238270 @default.
• W2105588894 cites W2265559286 @default.
• W2105588894 cites W2268887474 @default.
• W2105588894 cites W2329949221 @default.
• W2105588894 cites W2590151715 @default.
• W2105588894 cites W4210958476 @default.
• W2105588894 doi "https://doi.org/10.1200/jco.2012.45.3068" @default.
• W2105588894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23610112" @default.
• W2105588894 hasPublicationYear "2013" @default.
• W2105588894 type Work @default.
• W2105588894 sameAs 2105588894 @default.
• W2105588894 citedByCount "65" @default.
• W2105588894 countsByYear W21055888942013 @default.
• W2105588894 countsByYear W21055888942014 @default.
• W2105588894 countsByYear W21055888942015 @default.
• W2105588894 countsByYear W21055888942016 @default.
• W2105588894 countsByYear W21055888942017 @default.
• W2105588894 countsByYear W21055888942018 @default.
• W2105588894 countsByYear W21055888942019 @default.
• W2105588894 countsByYear W21055888942020 @default.
• W2105588894 countsByYear W21055888942021 @default.
• W2105588894 countsByYear W21055888942022 @default.
• W2105588894 countsByYear W21055888942023 @default.
• W2105588894 crossrefType "journal-article" @default.
• W2105588894 hasAuthorship W2105588894A5001188276 @default.
• W2105588894 hasAuthorship W2105588894A5004831613 @default.
• W2105588894 hasAuthorship W2105588894A5008883508 @default.
• W2105588894 hasAuthorship W2105588894A5012337396 @default.
• W2105588894 hasAuthorship W2105588894A5017871390 @default.
• W2105588894 hasAuthorship W2105588894A5025411863 @default.
• W2105588894 hasAuthorship W2105588894A5026031837 @default.
• W2105588894 hasAuthorship W2105588894A5031668702 @default.
• W2105588894 hasAuthorship W2105588894A5038448622 @default.
• W2105588894 hasAuthorship W2105588894A5051306896 @default.
• W2105588894 hasAuthorship W2105588894A5052920067 @default.
• W2105588894 hasAuthorship W2105588894A5061318948 @default.
• W2105588894 hasAuthorship W2105588894A5068970824 @default.
• W2105588894 hasAuthorship W2105588894A5070338465 @default.
• W2105588894 hasAuthorship W2105588894A5073613763 @default.
• W2105588894 hasAuthorship W2105588894A5082393642 @default.
• W2105588894 hasAuthorship W2105588894A5091359426 @default.
• W2105588894 hasBestOaLocation W21055888941 @default.
• W2105588894 hasConcept C121608353 @default.
• W2105588894 hasConcept C126322002 @default.
• W2105588894 hasConcept C143998085 @default.
• W2105588894 hasConcept C197934379 @default.
• W2105588894 hasConcept C207103383 @default.
• W2105588894 hasConcept C2775860665 @default.
• W2105588894 hasConcept C2777176818 @default.

• next